drugset
drugset / Trial / NCT02290886

A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral

NCT02290886 ↗

Phase 1/2 Completed 52 enrolled Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud Iniciativa Andaluza en Terapias Avanzadas · collab
RandomizedSingle-groupTriple-blindTreatment

Summary

A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells cells from adipose tissue in patients with Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start
2014-07
Primary completion
2022-03-02
Completion
2022-03-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous
Subject mesenchymal stem cells Cell therapy 4e+06 cells/kg Intravenous

Indications

amyotrophic lateral sclerosis